2022年1月15日土曜日
週1回投与のGLP-1受容体作動薬「Wegovy」(セマグルチド2.4 ...
Are YOU eligible for NHS's new 'miracle' weight loss injection? A million morbidly obese adults may be able to get a 'game-changing' once-a-week jab
- Appetite-suppressing injections could be available to millions of Britons
- NICE said the drug, already used for diabetes, should be given to obese people
- Trials found the drug slashed overweight and obese people's weight by 15%
The revolutionary once-a-week Wegovy jab — which experts believe could play a major role in combating the country's obesity crisis — was given the green light by the drug watchdog NICE.
Scientific studies have shown the fat-busting medicine works as well as gastric band surgery.
One trial showed patients given the treatment lost an average of nearly two-and-a-half stone (35lbs) in little over a year, while those given a placebo lost 6lbs.
University of Liverpool researchers who led the study described the drug as a 'game changer'.
Wegovy works by hijacking the body's own appetite regulating system in the brain, leading to reduced hunger cravings and calorie intake.
NICE has recommended the drug for people in England and Wales who have a BMI of 35 — making them morbidly obese, the fattest possible category — and have at least one weight-related comorbidity.
Those with a BMI between 30 and 35 could be recommended the drug, which costs £75 a month at a lower dose for diabetics, if they have been referred for specialist help.
Wegovy, a branded version of semaglutide made by pharmaceutical giant NovoNordisk, will be prescribed alongside a reduced-calorie diet and physical exercise programme.
The drug, which patients will be able to inject themselves, is already approved in the UK for type 2 diabetics.
Patients are told not to suddenly stop taking the drug without consulting their doctor. But some who have paid for it privately have stopped using it after seeing results within a matter of months.
The exact price NHS England is paying for the drug is confidential, but it will be given as a 2.4mg dose for obese people — double that given to diabetics.
A consultation on the recommendations made by the National Institute of Health and Care Excellence (NICE) is now open until March 1.
Medics will be asked to comment on the cost effectiveness of the medication, and the evidence of its fat-fighting effects.
NHS England can't make plans to rollout the drug until NICE's final guidance is released.
Around 12.4million adults in the UK are obese, making the country one of heaviest the world. Around 1.3million are thought to be morbidly obese.
The obesity epidemic costs the NHS £6.1billion and wider society £27billion every year, according to Government estimates.
Orlistat and liragultide are the only two anti-obesity drugs available on the NHS, while bariatric surgery is available to severely obese people who have a serious condition that could be improved with weight loss.
Doctors are already familiar with prescribing semaglutide in a lower dose, with type 2 diabetes sufferers injecting themselves with 1mg of the drug per week.
As an obesity treatment, the drug is self-injected once a week through a pen containing 2.4mg.
It triggers the body to produce a hormone called glucagon-like peptide-1 that is released naturally from the intestines after meals.
The hormone helps control blood sugar and makes people feel full so they know when to stop eating.
Trials of the drug, which has already received the greenlight in the US, found it was nearly twice as effective as other weight-loss drugs.
A trial of 1,961 participants across 16 countries, who weighed 16 stone 7lbs (105kg) and had a BMI of 38 on average, found participants lost 2 stone 6lbs (15.3kg) over 68 weeks. This equated to around 15 per cent of their body fat, on average.
US experts said the results are close to the effect of a gastric band, which cuts patients' body weight by around 25 per cent.
The group also received individual counselling sessions from registered dietitians to help them stick to a reduced-calorie diet and exercise plan, alongside the weekly injections.
Volunteers in the study, which was funded by Wegovy, reported improvement in their quality of life and a reduction in risk factors for developing heart disease and diabetes, such as reduced waist circumference, blood fats, blood sugar and blood pressure.
The drug triggered side effects include mild or moderate nausea and diarrhoea, but researchers said these were short-lasting and resolved themselves.
Professor Rachel Batterham, an obesity expert at University College London who co-authored the study, last year said the findings are a 'major breakthrough for improving the health of people with obesity'.
She said: 'No other drug has come close to producing this level of weight loss – this really is a gamechanger.
'For the first time, people can achieve through drugs what was only possible through weight-loss surgery.'
Helen Knight, programme director in the centre for health technology evaluation at NICE, said: 'We know that management of overweight and obesity is one of the biggest challenges our health service is facing with nearly two thirds of adults either overweight or obese.
'It is a lifelong condition that needs medical intervention, has psychological and physical effects, and can affect quality of life.
'But in recent years NICE has been able to recommend a new line of pharmaceutical treatments which have shown that those people using them, alongside changes to their diet and exercise, have been able to reduce their weight.'
The was approved as a weight-loss treatment by the US Food and Drug Administration in June.
Americans with a BMI higher than 27 with at least one weight-related condition are eligible for the drug, as well as all patients with a BMI above 30.
https://www.dailymail.co.uk/news/article-10488557/Game-changer-weight-loss-jab-prescribed-NHS-morbidly-obese.html
デブが毎週これを接種すればもうコロナは問題じゃなくなる。
Death汁により免疫が破壊された連中はもうToo Lateだけどね。（爆ｗｗｗｗｗｗｗｗ
2 件のコメント:
早い・安い・高カロリーのファーストフードは
添加物テンコ盛り・遺伝子組み換え野菜・抗生物質マミレの動物が使用されているわけで
これを20年30年食べ続ければ、肥満・成人病になるのは当然
「食生活を変える」という世界的大方針は、食品製造業界が断固シャットアウト
代わりに医薬品業界に「出番だよ」と分業推進
win-winの関係です
珍しく"対価"に触れない団長
それは多少安全だという事ではなく
デブ達その脂肪を早くなんとかしろ
各国もコロナ収束させたいのならば
デブの体重是正が最適解でしょう？
虚弱は天命に委ねるのみ悪しからず
こんな感じに解釈してるなうwww
コメントを投稿